FHA
NBIX icon

First Horizon Advisors’s Neurocrine Biosciences NBIX Stock Holding History

First Horizon Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$54.4K Buy
433
+48
+12% +$5.5K ﹤0.01% 956
2025
Q1 		$42.6K Sell
385
-480
-55% -$60.8K ﹤0.01% 1006
2024
Q4 		$118K Sell
865
-142
-14% -$17.6K ﹤0.01% 648
2024
Q3 		$116K Buy
1,007
+176
+21% +$24.1K ﹤0.01% 676
2024
Q2 		$114K Buy
831
+49
+6% +$6.72K ﹤0.01% 653
2024
Q1 		$108K Hold
782
– – ﹤0.01% 670
2023
Q4 		$103K Buy
782
+74
+10% +$8.52K ﹤0.01% 658
2023
Q3 		$79.7K Hold
708
– – ﹤0.01% 693
2023
Q2 		$66.8K Sell
708
-11
-2% -$1.07K ﹤0.01% 771
2023
Q1 		$72.8K Hold
719
– – ﹤0.01% 738
2022
Q4 		$85.9K Buy
719
+65
+10% +$7.61K ﹤0.01% 667
2022
Q3 		$69K Sell
654
-45
-6% -$4.57K ﹤0.01% 730
2022
Q2 		$67K Buy
699
+191
+38% +$17.6K ﹤0.01% 829
2022
Q1 		$48K Sell
508
-421
-45% -$35.7K ﹤0.01% 657
2021
Q4 		$78K Sell
929
-103
-10% -$9.47K ﹤0.01% 771
2021
Q3 		$98K Buy
1,032
+304
+42% +$28.7K ﹤0.01% 673
2021
Q2 		$70K Buy
728
+48
+7% +$4.6K ﹤0.01% 658
2021
Q1 		$65K Buy
680
+12
+2% +$1.26K ﹤0.01% 642
2020
Q4 		$63K Buy
668
+245
+58% +$23.7K ﹤0.01% 530
2020
Q3 		$40K Buy
423
+248
+142% +$28.7K ﹤0.01% 607
2020
Q2 		$21K Hold
175
– – ﹤0.01% 788
2020
Q1 		$15K Buy
175
+38
+28% +$3.72K ﹤0.01% 837
2019
Q4 		$15K Hold
137
– – ﹤0.01% 967
2019
Q3 		$12K Sell
137
-7
-5% -$654 ﹤0.01% 1025
2019
Q2 		$12K Hold
144
– – ﹤0.01% 1036
2019
Q1 		$13K Buy
+144
New +$12K ﹤0.01% 976

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Horizon Advisors's NBIX Position: Q2 2025 in Review

First Horizon Advisors increased its Neurocrine Biosciences (NBIX) stake by 12% in Q2 2025, buying an estimated $5.5K and bringing the position to 433 shares worth $54.4K. The position accounts for ﹤0.01% of the portfolio, ranked #956.

First Horizon Advisors first reported a position in NBIX in Q1 2019 and has held it in 26 quarters since. The position peaked at $118K in Q4 2024. 586 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • First Horizon Advisors held 433 shares of Neurocrine Biosciences worth $54.4K as of Q2 2025.
  • First Horizon Advisors bought 48 Neurocrine Biosciences shares in Q2 2025, an estimated $5.5K.
  • Neurocrine Biosciences made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #956 holding.
  • First Horizon Advisors first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 26 quarters since.
  • First Horizon Advisors's Neurocrine Biosciences position peaked at $118K in Q4 2024.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.